Novo Nordisk to launch weight-loss drug Wegovy in Australia this month
Danish drugmaker Novo Nordisk will launch its hugely popular weight-loss drug Wegovy in Australia this month, a spokesperson for the company said on Thursday.
Oxford Nanopore soars as Novo Nordisk builds stake
Oxford Nanopore Technologies PLC (LSE:ONT), the London-listed tech group, has rallied close to 12% this morning after it was revealed drug giant Novo Nordisk (NYSE:NVO) had bought a £50 million stake. a UK-listed company specialising in molecular sensing technology based on nanopores.
Focus: Patients push back against Novo Nordisk move to scrap an insulin product
Novo Nordisk's decision to stop selling its long-acting insulin Levemir in the United States has left some diabetes patients struggling to switch treatments, patients and doctors in a dozen U.S. states told Reuters.
Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing
Novo Nordisk (NVO) concluded the recent trading session at $128.05, signifying a +1.04% move from its prior day's close.
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
This Could Send Ozempic's Sales Potential to a Whole Other Level
Ozempic's potential usefulness continues to grow as more studies are done on the diabetes drug. There are multiple potential brain benefits related to using the drug, which could unlock more growth opportunities.
Novo Nordisk's Next-Gen Diabetes Candidate Could Challenge Ozempic -- Is the Stock a Buy?
There are dozens of investigational GLP-1 medicines in development. Novo Nordisk, the leader in the field, arguably has the most promising candidates.
Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?
Novo Nordisk's (NVO) second-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.
Novo Nordisk's Wegovy wins EU backing for reducing heart risks
Novo Nordisk's blockbuster Wegovy weight loss drug has received backing from the European Union's medical regulator to expand its use to include reducing the rise of serious heart events in overweight and obese adults. The Danish pharmaceutical giant said Thursday that the European Medical Agency had adopted a "positive opinion" on the label expansion, after reviewing the outcomes of a closely watched SELECT trial.
EU regulator backs use of Novo's Wegovy to lower heart risks
The European Medicines Agency has backed the use of Novo Nordisk's Wegovy to lower heart risks in overweight or obese adults, the company said on Thursday.
Wegovy approved in UK for cardiovascular problems in obese adults
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved semaglutide, known commercially as Wegovy, to reduce the risk of serious heart problems or strokes in overweight and obese adults. This approval makes semaglutide the first weight loss drug in the UK prescribed to prevent cardiovascular events in individuals with established cardiovascular disease.
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
In the most recent trading session, Novo Nordisk (NVO) closed at $133.28, indicating a +0.08% shift from the previous trading day.
